Evidence map›Paper›PMID 29242250›Full record

Trial reportJournal of the American Society of Nephrology : JASN2018

A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection.

Farsad Eskandary, Heinz Regele, Lukas Baumann, Gregor Bond, Nicolas Kozakowski, Markus Wahrmann, Luis G Hidalgo, Helmuth Haslacher, Christopher C Kaltenecker, Marie-Bernadette Aretin and 7 more

2 registry-linked trialsOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the American Society of Nephrology : JASN, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 128 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
128citing papers in PubMed, 3 pooled it
21.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03444103 phase2completednot on this map

Safety, Tolerability and Efficacy of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Rejection After Kidney Transplantation - a Pilot Trial

TypeinterventionalSponsorMedical University of ViennaRan2018 to 2020Enrolled20ConditionsAntibody-mediated RejectionArmsClazakizumab / Clazakizumab, Placebo / Clazakizumab
NCT03859388 active not recruitingnot on this mapstarted 2019, after this paper: background citation

Use of Donor-Derived Cell-Free DNA to Characterize Response to Therapy With Tocilizumab for Chronic Antibody-Mediated Rejection in Kidney Transplantation

TypeobservationalSponsorCedars-Sinai Medical CenterRan2019 to 2025Enrolled10ConditionsRejection Chronic Renal, Kidney Transplant Rejection
3 · Its place in the literature

Who cites it

128 citing papers in PubMed, 3 syntheses or guidelines pooled it, 294 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Donor-derived cell-free DNA monitoring for early diagnosis of antibody-mediated rejection after kidney transplantation: a randomized trial.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025
    Trial
  6. Anti-interleukin-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection: effect on cytochrome P450 drug metabolism.Transplant international : official journal of the European Society for Organ Transplantation · 2021
    Trial
  7. Trial
  8. Trial
  9. Review
  10. Article
  11. Mechanisms and Determinants of CMV Reactivation in Kidney Transplantation.International journal of molecular sciences · 2026
    Review
  12. Observational
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

68 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 2 countries.

Farsad EskandaryDivision of Nephrology and Dialysis, Department of Medicine III.
Heinz RegeleDepartments of Pathology.
Lukas BaumannCenter for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria.
Gregor BondDivision of Nephrology and Dialysis, Department of Medicine III.
Nicolas KozakowskiDepartments of Pathology.
Markus WahrmannDivision of Nephrology and Dialysis, Department of Medicine III.ORCID 0000-0002-1301-8694
Luis G HidalgoDepartment of Laboratory Medicine and Pathology and.
Helmuth HaslacherLaboratory Medicine, and.
Christopher C KalteneckerDivision of Nephrology and Dialysis, Department of Medicine III.
Marie-Bernadette AretinPharmacy Department, General Hospital Vienna, Vienna, Austria.
Rainer OberbauerDivision of Nephrology and Dialysis, Department of Medicine III.
Martin PoschCenter for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria.
Anton StaudenherzBiomedical Imaging and Image-Guided Therapy, and.
Ammon HandisuryaDivision of Nephrology and Dialysis, Department of Medicine III.
Jeff ReeveAlberta Transplant Applied Genomics Centre, University of Alberta, Edmonton, Alberta, Canada; and.
Philip F HalloranAlberta Transplant Applied Genomics Centre, University of Alberta, Edmonton, Alberta, Canada; and.
Georg A BöhmigDivision of Nephrology and Dialysis, Department of Medicine III, georg.boehmig@meduniwien.ac.at.
Medical University of Vienna · ATThe Metabolomics Innovation Centre · CAUniversity of Alberta · CAVienna General Hospital · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Late antibody-mediated rejection (ABMR) is a leading cause of kidney allograft failure. Uncontrolled studies have suggested efficacy of the proteasome inhibitor bortezomib, but no systematic trial has been undertaken to support its use in ABMR. In this randomized, placebo-controlled trial (the Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection [BORTEJECT] Trial), we investigated whether two cycles of bortezomib (each cycle: 1.3 mg/m

Indexed as

Kidney TransplantationAdultAllograftsAntibodiesBortezomibDisease ProgressionDouble-Blind MethodFemaleGlomerular Filtration RateGraft RejectionGraft SurvivalHLA AntigensHumansMaleMiddle AgedProspective StudiesAntibodiesBortezomibHLA AntigensProteasome Inhibitorsantibody-mediated rejectionbortezomibchronic allograft failurekidneyrandomized controlled trialtransplantation

Identifiers

PMID29242250
PMCPMC5791086
OpenAlexW2773812249

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.